Overview
Kleefstra syndrome (also known as 9q34 deletion syndrome or 9q subtelomeric deletion syndrome) is a rare genetic neurodevelopmental disorder characterized primarily by intellectual disability, childhood hypotonia (low muscle tone), and a distinctive facial appearance. The condition is caused either by a microdeletion of the 9q34.3 chromosomal region or by loss-of-function mutations in the EHMT1 gene (euchromatic histone methyltransferase 1), which encodes a histone methyltransferase important for normal brain development and function. The syndrome affects multiple body systems. Neurological features include moderate to severe intellectual disability, speech and language delay (with expressive language often more severely affected), and behavioral characteristics such as autism spectrum features, apathy, and intermittent aggression. Seizures occur in a significant proportion of patients. The characteristic facial features include microcephaly, flat midface, hypertelorism, arched eyebrows, short nose with anteverted nares, everted lower lip, and a protruding tongue. Congenital heart defects are present in approximately 30-50% of individuals, with a range of structural anomalies reported. Other features may include renal and urogenital anomalies, hearing loss, obesity, and sleep disturbances. Some patients experience a regression-like phenotype in adolescence or adulthood, characterized by severe apathy, catatonia-like features, and behavioral deterioration. There is currently no cure or disease-specific treatment for Kleefstra syndrome. Management is supportive and multidisciplinary, involving early intervention programs, speech and occupational therapy, behavioral support, and monitoring for associated complications such as cardiac defects, epilepsy, and sleep apnea. Psychiatric symptoms, including catatonia-like episodes, may require careful pharmacological management. Regular developmental assessments and screening for comorbidities are essential components of long-term care.
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Kleefstra syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Kleefstra syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Kleefstra syndrome.
Community
No community posts yet. Be the first to share your experience with Kleefstra syndrome.
Start the conversation →Latest news about Kleefstra syndrome
No recent news articles for Kleefstra syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Kleefstra syndrome
What is Kleefstra syndrome?
Kleefstra syndrome (also known as 9q34 deletion syndrome or 9q subtelomeric deletion syndrome) is a rare genetic neurodevelopmental disorder characterized primarily by intellectual disability, childhood hypotonia (low muscle tone), and a distinctive facial appearance. The condition is caused either by a microdeletion of the 9q34.3 chromosomal region or by loss-of-function mutations in the EHMT1 gene (euchromatic histone methyltransferase 1), which encodes a histone methyltransferase important for normal brain development and function. The syndrome affects multiple body systems. Neurological f
How is Kleefstra syndrome inherited?
Kleefstra syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Kleefstra syndrome typically begin?
Typical onset of Kleefstra syndrome is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Kleefstra syndrome?
15 specialists and care centers treating Kleefstra syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.